Ozempic Re-Titration After Stopping: How to Safely Restart Semaglutide At a glance Starting re-titration dose / 0.25 mg subcutaneous once weekly Minimum time at 0.25 mg before advancing / 4 weeks Standard step to 0.5 mg / after 4 weeks at 0.25 mg Next available doses / 1.0 mg, then 1.7 mg, then 2.0 mg Minimum weeks per dose step (tolerability permitting) / 4 weeks Gap that triggers mandatory re-titration / more than 5 weeks since last dose Primary GI risk if steps are skipped / nausea and vomiting in up to 44% of patients Half-life of semaglutide / approximately 7 days (one week) Approved indications for Ozempic / type 2 diabetes (also cardiovascular risk reduction in T2D) Key trial supporting dose escalation design / SUSTAIN-7 (N=1,201) Why Re-Titration Is Necessary After Stopping Ozempic When you stop Ozempic, semaglutide's GLP-1 receptor agonism fades within 5 to 7 half-lives, roughly 5 to 7 weeks

Ozempic: Approved by the FDA on June 4, 2021, for chronic weight management in patients with obesity (body mass index of 30 or more) and overweight (body mass index of 27 or more) with a weight-related condition like cardiovascular disease, high blood pressure, or type 2 diabetes
Glycemic and Anthropometric Secondary Outcomes Participants in the 6 mg group demonstrated a 2.4 mmol/mol reduction in HbA1c compared with a 0.1 mmol/mol reduction in the placebo group (p = 0.006)
If your commercial insurance covers Wegovy, you can get a monthly supply of Wegovy for $0 with the Wegovy savings card
Key takeaways Semaglutide can interact with levothyroxine, so close monitoring of TSH levels and medication adjustments are needed
Reporting adverse events If you experienced a negative reaction to a grey market or compounded tirzepatide product, consider reporting it to the FDA MedWatch program